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Background: A series of 6-(substituted aldehyde)-3,4-dihydro-1-(tetrahydro-3,4-dihydroxy-5-(hydroxymethyl)
furan-2-yl)-4-phenylpyrimidine-2(1H)-one derivative (6A-6P) was synthesized from the 6-(substituted aldehyde)-4-
phenylpyrimidine-2(1H)-one derivative (5A-5P) through following reaction mechanisms Claisen-Schmidt, Cyclization,
and Satos fusion. The structures of the synthesized compounds were elucidated by I.R.,1H-NMR, elemental analysis,
and mass spectroscopic techniques.
Result: The synthesized compounds were screened for in vitro antifungal activity at 25, 50, 100, and 200 μg/ml
concentrations. Among them, compounds 6P, 6D, and 6M exhibited significant antifungal activity that was carried
out by cup plate method against fungal strain which was collected from IMTECH Chandigarh, India, against
standard drug fluconazole. Compounds have been further evaluated by measuring zone of inhibition and percent
inhibition. The synthesized compounds were screened for in vitro antioxidant activity using the DPPH assay, based
on the AAI and antioxidant activity unit (AAU), using a combination relation between DPPH concentration and
absorbance. The antioxidant strength of compounds was compared against ascorbic acid. Among them,
compounds 6K, 6F, 6E, 6G, 6H, and 6M exhibited significant antioxidant activity and 6J have less active compound.
The data of these synthesized compounds were submitted to the National Institute of Health, USA, under the drug
discovery program of National Cancer Institute (NCI) and screened for anticancer activity at a single high dose
(10−5 M) in full NCI 60 cell lines. The selected compounds have shown potent significant anticancer activity in the
NCI 60 cell line screening.
Conclusion: A new series of pyrimidine analogues that contain furanose moiety were synthesized by Satos fusion
and characterized. The synthesized compounds screened for their in vitro antioxidant, antifungal activity, as well as
anticancer activity given by the derivative which has chloro, methoxy, nitro, and chloro substitution having furanose
contain pyrimidine derivative that showed the most potent activity.
Keywords: Pyrimidine; Anticancer; Antifungal; AntioxidantBackground
Pyrimidine is a six-member heterocyclic compound that
contains two nitrogen atoms at positions 1 and 3. Pyrimi-
dines, being an integral part of DNA and RNA impart to
diverse pharmacological properties as effective bactericide
and fungicides [1], nitrogen containing heterocyclic ring
such as pyrimidine is a promising structural moiety for
drug designing. Pyrimidine derivatives form a component
in a number of useful drugs and are associated with many* Correspondence: rdudhe121@rediffmail.com
1Uttarakhand Technical University, Dehradun, Uttarakhand 284007, India
2Department of Pharmacy, SMAS, Galgotias University, Greater Noida, Uttar
Pradesh 201306, India
Full list of author information is available at the end of the article
© 2014 Dudhe et al.; licensee Springer. This is a
Attribution License (http://creativecommons.or
in any medium, provided the original work is pbiological and therapeutically activities [2]. Condensed
furanose pyrimidine derivatives have been reported as
antioxidant [3], antimicrobial [4], analgesic [5], antiviral
[6], anti-inflammatory [7], anti-HIV [8], antitubercular [9],
antitumor [10], antineoplastic [11], and antimalarial [12].
The condensed furanose pyrimidine derivative has the
power to accept free radical during different abovemen-
tioned diseases due to the presence of NH and OH
molecule in ring.
Free radicals are well known for playing a dual role in
our body, deleterious as well as beneficial. It includes
metabolic pathway for its generation [13]. It mainly ex-
plores the formation and the scavenging of free radi-
cals, as well as the damage caused by free radicals inn Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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due to excessive generation of free radical and reduced
level of antioxidant, but at low concentration, these
radicals performs normal physiological functions of
body. Scientific evidence suggests that antioxidants re-
duce the risk for chronic diseases including cancer and
heart disease [14].
About 13% deaths of human beings throughout the
world are caused by cancer, which is characterized by
uncontrolled cell growth, metastasis, and invasion [13].
Although the risk of cancer increases with age, people
of all ages, even fetuses, can be affected by the disease.
The most occurring fatal cancers are lung, stomach,
liver, colon, and breast cancer. Therefore, continuous
search for new anticancer agents should be an active
work in the research field at various laboratories.
Among potential anticancer agents, heterocyclic com-
pounds represent an outstanding type of anticancer
drug moiety (Figure 1).
Free radical may be defined as the atoms, molecules,
or ions with unpaired electrons in an open shell config-
uration. Sometime, free radicals may contain positive,
negative, or zero charge [15]. Free radicals play an im-
portant role in combustion, atmospheric chemistry,
polymerization, plasma chemistry, and many other chem-
ical processes [16]. The large generation of free radicals
particularly reactive oxygen species and their high activity
plays an important role in the progression of great number
of pathological disturbances such as inflammation [17],
atherosclerosis [18], cancer [19], parkinsonism [20], and
Alzheimer's disease [21]. Inflammation is mostly caused




All the reagents and solvents used were laboratory grade
and obtained from the supplier (Sigma-Aldrich, St. Louis,
MO, USA; CDH, Beijing, China; and Rankem, Faridabad,
India) or recrystallized/redistilled as necessary. The purityFigure 1 Mechanism of anticancer compound.of compounds synthesized, commercial reagents used, and
monitor of reaction was done by thin layer chromatog-
raphy (TLC) plates (silica gel G). Two solvent systems:
toluene/ethyl acetate/formic acid (5:4:1) and ethyl acetate/
n-hexane (3:7) were used to run TLC. The spots were
located under iodine vapors and UV light. The melting
points of the products were determined by open capillaries
method and are uncorrected. Infrared (IR) spectra (KBr)
were recorded on FTIR spectrophotometer (Shimadzu
FTIR 8400 S, 4,000 to 400 cm−1, Kyoto, Japan). The
elemental analysis was carried out using Heraus CHN
rapid analyzer (Hanau, Germany) [1].H-NMR spectra
were recorded on a JEOL AL300 FTNMR 300 MHz
spectrometer (Akishima-shi, Japan) in dimethyl sulfoxide
(DMSO) using TMS as an internal standard, with [1] H
resonance frequency of 300 MHz chemical shift values are
expressed in δ ppm. The activity was performed on instru-




All the synthesized compound were screened in vitro for
their antifungal activity Candida inconspicua (Microbial
Type culture collection (MTCC)-1074, American Type
Culture Collection (ATCC)-16783), Candida viswanathii
(MTCC-1629, ATCC-22981), Candida albicans (MTCC-
227, ATCC-10231), Candida tropicalis (MTCC-230,
ATCC-20336), Candida glabrata (MTCC-3019, ATCC-
90030) against standard drug fluconazole [19]. The in-
cubation time was 48 h at 37°C for fungal strain. All the
screened compounds were found to possess moderate
to good antifungal activity. The cup plate test was per-
formed using agar medium and dextrose agar medium,
and the medium was autoclaved at 15 lbs pressure (121°C)
for 15 min then immediately cooled to 50°C to 55°C in
a water bath after removing it from autoclave. The
cooled medium was poured into sterile petri plates to a
uniform depth of 4 mm or 25 ml in a 90-mm plate.
Once the medium had solidified, then the culture was
Figure 2 Effect of free radical in the body parts.
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dipped into the fungus suspension or inoculated with
1 ml of the organism suspension. Sterillized 9-mm cork
borer was used to make agar wells, than placed 25, 50,
100 and 200 μg/ml diluted test compound as well as
standard compound were placed into each wells and
DMSO as a control. The plate were inoculate for 48 h
at 37°C for fungal strain and measure zone of inhib-
ition in mm and the percentage (%) of inhibition was
calculated by using the formula [17] (Tables 1, 2, 3, 4
and 5) (Figures 3, 4, 5, 6 and 7).
%of inhibition ¼ Diameterof the inhibitionzone inmm
Diameterof thepetri plates inmm 90ð Þ
Free radical scavenging method by DPPH assay
Various concentrations of test compound 10 to 200 μg/ml
were prepared in the methanol and 1 ml of each concen-
tration was added to 1 ml of 0.1 mM solution of DPPH
[3]. The mixture was shaken vigorously and allowed to
stand for 30 min in dark place; absorbance at 517 nm was
determined by UV spectrometer, and the percentage scav-
enging activity was calculated. A blank solution of DPPH
was prepared, and ascorbic acid was used as reference
compound. All the compounds were tested and analyzed
by their absorbance. The equation used to measure free
radical scavenging is as follows (Equation 1, Figure 8,
Scheme 1):
A lower value of mean inhibitory concentration shows
a higher free radical scavenging activity.%Scavenging ¼ Absorbanceof control−Absorbanceof tes
Absorbanceof controlAAU equation
The free radical scavenging fitting curve equation (y =
BX + D) when combined with theoretical value of DPPH
concentration and absorbance (y = KX) to assume the
index antioxidant activity unit (AAU), it is defined as
‘one mole of DPPH free radical was completely scav-
enged to consume amount (mole number) of the scaven-
ger’. The lower the value of AAU, the stronger the
antioxidant ability of compound (Table 6) (Figure 9).
AAU ¼ 394:32 R
B CMr ;
where R = solution volume ratio of sample to solution
volume of DPPH for each sample, B = slope of fitting
equation of free radical scavenging ratio, C = initial con-
centration of DPPH solution observed, and Mr =mo-
lecular weight of sample.
Anticancer screening
Pharmacological evaluation of the anticancer activity was
performed on the compounds inconvertibly selected by
the National Institute of Health, Bethesda, USA, under
the drug discovery program of National Cancer Institute
(NCI) [13]. All the finally synthesized 20 compounds
have been registered on its website, and from those,
only 13 compounds have been selected. All the selected
compounds have been given a unique NCI number [19].
Methodology of the in vitro cancer screening
The human tumor cell lines of the cancer screening
panel are grown in RPMI 1640 medium containing 5%
fetal bovine serum and 2 μL glutamine. The cells aret compounds=Std: 100
Table 1 Antifungal activity for MTCC-230 strain
Compounds % Inhibition at μg/ml MTCC-230
25 50 100 200
Standard 21.11 22.89 25.33 27.56
6B 19.11 22 24 26.44
6C 17.11 20 21.7 22.24
6E 26 27.33 28 28.66
6F 20.22 22.26 23.55 24
6G 17.11 18 22 22.04
6I 19.11 20.66 22.66 21.2
6K 20.4 22.22 24 26.66
6M 20.44 21.7 23.55 25.2
6P 15.33 20.66 26.66 29.1
Table 3 Antifungal activity for MTCC-1074
Compounds % Inhibition at μg/ml MTCC-1074
25 50 100 200
Standard 15.33 18.44 22.00 25.33
6C 0 17.77 20 21.33
6D 20.44 22.24 23.33 24.22
6E 15.55 17.55 19.11 22.66
6F 18.66 21.33 23.11 25.77
6G 0 0 13.77 15.88
6H 0 0 14.44 16.88
6I 15.33 16.88 18.22 20.97
6J 18.66 19.55 21.55 22.66
6K 20.22 22.22 25.55 27.77
6M 17.11 19.11 22 26
6P 16.66 19.11 20.44 23.77
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plating densities ranging from 5,000 to 40,000 cells/well
depending on the doubling time of individual cell lines.
After cell inoculation, the microtiter plates are incubated
at 37°C in the presence of 5% CO2, 95% air, and 100%
relative humidity for 24 h prior to addition of experi-
mental drugs. After 24 h, two plates of each cell line are
fixed in situ with TCA to represent a measurement of
the cell population for each cell line at the time of drug
addition (Tz). Experimental drugs are solubilized in di-
methyl sulfoxide at desired final maximum test concen-
tration and stored frozen prior to use. At the time of
drug addition, an aliquot of frozen concentrate is thawed
and diluted to twice the desired final maximum test con-
centration with complete medium containing 50 μg/ml
gentamicin. Additional 4-, 10-fold, or ½ log serial dilu-
tions are made to provide a total of five drug concentra-
tions plus control. Aliquots of 100 μl of these different
drug dilutions are added to the appropriate microtiterTable 2 Antifungal activity for MTCC-3019
Compounds % Inhibition at μg/ml MTCC-3019
25 50 100 200
Standard 14.00 16.44 19.56 22.00
6B 17.33 19.33 20 22.22
6C 0 0 12.22 13.11
6D 0 12.22 14.44 17.11
6E 0 0 13.11 13.77
6F 14.44 15.77 17.77 20.44
6G 16.88 18.88 20.04 21.33
6H 0 12.88 14.22 15.77
6J 0 0 12.44 14.44
6M 15.55 16.88 19.55 21.55
6n 13.33 15.77 17.55 19.11
6P 15.3 17.07 18.44 20.88wells already containing 100 μl of medium, resulting in
the required final drug concentrations.
After the following drug addition, the plates are incu-
bated for an additional 48 h at 37°C, 5% CO2, 95% air,
and 100% relative humidity. For adherent cells, the assay
is terminated by the addition of cold TCA. Cells are
fixed in situ by the gentle addition of 50 μl of cold 50%
(w/v) TCA (final concentration, 10% TCA) and incu-
bated for 60 min at 4°C. The supernatant is discarded,
and the plates are washed five times with tap water and
air dried. Sulforhodamine B (SRB) solution (100 μl) at
0.4% (w/v) in 1% acetic acid is added to each well, and
plates are incubated for 10 min at room temperature.
After staining, unbound dye is removed by washing five
times with 1% acetic acid and the plates are air dried.
Bound stain is subsequently solubilized with 10 mM
trizma base, and the absorbance is read on an automated
plate reader at a wavelength of 515 nm. For suspension
cells, the methodology is the same except that the assayTable 4 Antifungal activity for MTCC-227
Compounds % Inhibition at μg/ml MTCC-227
25 50 100 200
Standard 16.44 19.33 23.33 27.33
6B 14 16 16.88 18.66
6C 16.88 18.22 19.55 20.44
6D 20.2 24 29.33 34.66
6E 15.77 18.66 21.55 26.22
6E 13.77 14.66 16.22 18
6G 13.11 14 14.66 15.33
6H 14.66 17.11 19.11 22.8
6J 0 13.77 15.11 16.88
6K 0 0 13.77 16.22
Table 5 Antifungal activity for MTCC-1629
Compounds % Inhibition at μg/ml MTCC-1629
25 50 100 200
Standard 16.44 19.33 23.33 27.33
6C 13.11 14.66 16.22 18
6D 17.33 19.77 22.6 25.53
6F 23.55 26.22 28 30.44
6G 21.33 24 26.11 30.22
6I 14.66 16.44 18 21.55
6J 14.22 16.22 19.11 23.77
6K 21.55 23.55 27.33 31.55
6M 15.11 16.44 18 21.55
6P 21.77 23.77 25.77 28.66
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wells by gently adding 50 μl of 80% TCA (final concen-
tration, 16% TCA). Using the seven absorbance mea-
surements (time zero, (Tz), control growth, (C), and test
growth in the presence of drug at the five concentration
levels (Ti)), the percentage growth is calculated at each
of the drug concentrations levels. Percentage growth in-
hibition is calculated as:
Ti−Tzð Þ= C−Tzð Þ½   100 for concentrations
for which Ti > = ¼ Tz
Ti−Tzð Þ=Tz½   100 for concentrations for
which Ti < Tz:
Three dose response parameters are calculated for each
experimental agent. Growth inhibition of 50% (GI50) is
calculated from [(Ti −Tz)/(C −Tz)] × 100 = 50, which is
the drug concentration resulting in a 50% reduction in the
net protein increase (as measured by SRB staining) in con-
trol cells during the drug incubation. The drug concentra-
tion resulting in total growth inhibition (TGI) is calculated
from Ti = Tz. The LC50 (concentration of drug resulting
in a 50% reduction in the measured protein at the end of
the drug treatment as compared to that at the beginning)
indicating a net loss of cells following treatment is

















Figure 3 Antifungal activity of synthesized compound against Candidcalculated for each of these three parameters if the level
of activity is reached; however, if the effect is not
reached or is exceeded, the value for that parameter is
expressed as greater or less than the maximum or mini-
mum concentration tested. The compounds which re-
duce the growth of any one of the cell lines by 32% or
less are passed on for further evaluation in the full panel
of 60 cell lines (Table 7) (Figures 10, 11, 12 and 13).
General procedures for the synthesis of compounds
Synthesis of compounds (3A-3P)
Equimolar portions of the appropriately substituted aro-
matic aldehyde (10 mmol) and acetophenone (10 mmol)
were dissolved in approximately in 15 ml of ethanol.
The mixture was allowed to stir for several minutes at
5°C to 10°C. Then, 10 ml of 40% aq. NaOH solution was
added dropwise to the reaction mixture in the conical
flask. The reaction mixture then allowed stirring at room
temperature for 4 h on stirrer and precipitate is allowed to
stand overnight in refrigerator. Precipitate is formed which
is collected by filtration and repeatedly washed with dis-
tilled water and finally recrystallized in ethanol. The solv-
ent system was used for the TLC ethyl acetate/n-hexane
(3:7) (Scheme 2).
Synthesis of 3-phenyl-1-phenylprop-2-en-1-one (chal-
cone) (3A): It was obtained by reaction of acetophenon
with benzaldehyde. Molecular formula, C17H16O3; molecu-
lar weight, 208; m.p., 58°C to 60°C; Rf. value (ethyl acetate/
n-hexane, 3:7), 0.78; IR (KBr, cm−1), 3,001.03(C-H stretch.),
1,660.60(conj. C = C), 1,604.66(Ar. C = C), 1,288.36(Ar.
C-O), 688.54(Ar. C-H bend).
Synthesis of 3-(3,4-dimethoxyphenyl)-1-phenylprop-
2-en-1-one (3B): It was obtained by reaction of aceto-
phenon (2) with 3,4-dimethoxy benzaldehyde. Molecular
formula, C17H16O3; molecular weight, 268; m.p., 76°C to
78°C; Rf. value (ethyl acetate/n-hexane, 3:7), 0.80; I.R.
(KBr, cm−1), 2,939.31(C-H str.), 1,654.81(conj. C = C),
1,587.31(Ar. C = C), 1,255.57(Ar. C-O), 698.18(Ar. C-H
bend).
Synthesis of 3-(2-methoxyphenyl)-1-phenylprop-2-
en-1-one (3C): It was obtained by reaction of acetophe-

























Figure 4 Antifungal activity of synthesized compound against Candida glabrata (MTCC-3019).
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value (ethyl acetate/n-hexane, 3:7), 0.72; I.R. (KBr, cm−1),
1,670.44(conj. C = C), 1,602.74(Ar. C = C), 1,249.79(Ar.
C-O), 692.40(Ar. C-H bend).
Synthesis of 3-(4-methoxyphenyl)-1-phenylprop-2-
en-1-one (3D): It was obtained by reaction of acetophe-
non with 4-methoxy benzaldehyde. Molecular formula,
C16H14O2; molecular weight, 238; m. p., 72°C to 74°C; Rf.
value (Ethyl acetate/n-hexane, 3:7), 0.76; I.R. (KBr, cm−1),
1,656.74(conj. C = C), 1,600.81(Ar. C = C), 1,213.14(Ar.
C-O), 688.54(Ar. C-H bend.).
Synthesis of 3-(2-chlorophenyl)-1-phenylprop-2-en-1-
one (3E): It was obtained by reaction of acetophenon with
2-chloro benzaldehyde. Molecular formula, C15H11ClO;
molecular weight, 242; m. p., 55°C to 57°C; Rf. value (ethyl
acetate/n-hexane, 3:7), 0.78; I.R. (KBr, cm−1), 2,956.67
(C-H str.), 1,660.60(conj. C = C), 1,577.66(Ar. C = C),
1,249.79(Ar. C-O), 752.19 (C-Cl), 692.40(Ar. C-H bend.).
Synthesis of 3-(4-chlorophenyl)-1-phenylprop-2-en-1-
one (3F): It was obtained by reaction of acetophenon- with
4-chloro benzaldehyde. Molecular formula, C15H11ClO;
molecular weight, 242; m. p., 80°C to 84°C; Rf. value
(ethyl acetate/n-hexane, 3:7), 0.75; I.R. (KBr, cm−1),
2,918.10(C-H, str.), 1,658.67(conj. C = C), 1,602.74 (Ar.
C = C), 1,217.00(Ar. C-O), 775.33 (C-Cl), 690.47(Ar. C-H
bend.).
Synthesis of 3-(2, 4-dichlorophenyl)-1-phenylprop-2-
















Figure 5 Antifungal activity of synthesized compound against Candidwith 2,4-dichlorobenzaldehyde. Molecular formula,
C15H10Cl2O; molecular weight, 277; m. p., 70°C to 72°C; Rf.
value (ethyl acetate/n-hexane, 3:7), 0.72; I.R. (KBr, cm−1),
2,958.60(C-H str.), 1,662.52(conj. C = C), 1,608.52(Ar.
C = C), 1,286.36(Ar. C-O), 713.61 (C-Cl), 684.68(Ar. C-H
bend.).
Synthesis of 3-(2, 6-dichlorophenyl)-1-phenylprop-
2-en-1-one (3H): It was obtained by reaction of aceto-
phenon with 2,6-dichlorobenzaldehyde. Molecular formula,
C15H10Cl2O; molecular weight, 277; m. p., 76°C to
78°C; Rf. value (ethyl acetate/n-hexane, 3:7), 0.74; I.R.
(KBr, cm−1), 3,082.04(C-H str.), 1,660.60(conj. C = C),
1,612.38(Ar. C = C), 1,265.22(Ar. C-O), 719.40 (C-Cl),
696.25(Ar. C-H bend.).
Synthesis of 3-(2-fluorophenyl)-1-phenylprop-2-en-1-
one (3I): It was obtained by reaction of acetophenon with
2-fluorobenzaldehyde. Molecular formula, C15H11FO; mo-
lecular weight, 226; m. p., 38°C to 40°C; Rf. value (ethyl
acetate/n-hexane, 3:7), 0.78; I.R. (KBr, cm−1), 3,028.03(C-H
str.), 1,641.31(conj. C = C), 1,612.38(Ar. C = C), 1,384.79
(C-F), 1,244.36(Ar. C-O), 686.61(Ar. C-H bend.).
Synthesis of 3-(4-fluorophenyl)-1-phenylprop-2-en-1-
one (3J): It was obtained by reaction of acetophenon with
4-flurobenzaldehyde. Molecular formula, C15H11FO; mo-
lecular weight, 226; m. p., 40°C to 42°C; Rf. value (ethyl
acetate/n-hexane, 3:7), 0.80; I.R. (KBr, cm−1), 1,696.60
(conj. C = C), 1,609.59(Ar. C = C), 1,382.87 (C-F), 1,213.14



























Figure 6 Antifungal activity of synthesized compound against Candida albicans (MTCC-227).
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one (3K): It was obtained by reaction of acetophenon with
4-bromobenzaldehyde. Molecular formula, C15H11BrO;
molecular weight, 287; m. p., 112°C to 114°C; Rf. value
(ethyl acetate/n-hexane, 3:7), 0.72; I.R. (KBr, cm−1),
3,056.96(C-H str.), 1,658.67(conj. C = C), 1,608.52(Ar.
C = C), 1,332.72(Ar. C-O), 688.54(Ar. C-H bend), 532.32
(C-Br).
Synthesis of 3-(2-nitrophenyl)-1-phenylprop-2-en-1-
one (3L): It was obtained by reaction of acetophenon with
2-nitrobenzaldehyde. Molecular formula, C15H11NO3;
molecular weight, 253; m. p., 78°C to 80°C; Rf. value
(ethyl acetate/n-hexane, 3:7), 0.68; I.R. (KBr, cm−1),
3,006.82(C-H str.), 1,631.67(conj. C = C), 1,382.87 (Ar-
NO2), 1,276.79(Ar. C-O), 686.88(Ar. C-H bend).
Synthesis of 3-(3-nitrophenyl)-1-phenylprop-2-en-
1-one (3M): It was obtained by reaction of acetophenon
with 3-nitrobenzaldehyde. Molecular formula, C15H11NO3;
molecular weight, 253; m. p., 68°C to 70°C; Rf. value (ethyl
acetate/n-hexane, 3:7), 0.66; I.R. (KBr, cm−1), 2,918.10
(C-H str.), 1,662.52(conj. C = C), 1,608.52(Ar. C = C),
1,529.45(Ar-NO2), 1,218.93(Ar. C-O), 655.75(Ar. C-H
bend.).
Synthesis of 3-(4-nitrophenyl)-1-phenylprop-2-en-1-
one (3N): It was obtained by reaction of acetophenon with
4-nitrobenzaldehyde. Molecular formula, C15H11NO3;
molecular weight, 253; m. p., 62°C to 74°C; Rf. value

















Figure 7 Antifungal activity of synthesized compound against Candid2,968.24(C-H str.), 1,629.74(conj. C = C), 1,595.02(Ar.
C = C), 1,384.79 (Ar-NO2), 1,218.93(Ar. C-O), 684.68
(Ar. C-H bend).
Synthesis of 3-(2,4-dinitrophenyl)-1-phenylprop-2-
en-1-one (3O): It was obtained by reaction of acetophe-
non with 2,4-dinitrobenzaldehyde. Molecular formula,
C15H10N2O5; molecular weight, 253; m. p., 92°C to 94°C;
Rf. value (ethyl acetate/n-hexane, 3:7), 0.78; I.R. (KBr,
cm−1), 2,918.10(C-H str.), 1,631.67(conj. C = C), 1,531.37
(Ar-C-NO2), 1,384.79 (Ar-NO2), 1,218.93(Ar. C-O),
688.54(Ar. C-H bend.).
Synthesis of 3-(3, 4, 5-trimethoxyphenyl)-1-phenyl-
prop-2-en-1-one (3P): It was obtained by reaction of
acetophenon with 3,4,5-trimethoxybenzaldehyde. Molecu-
lar formula, C18H18O4; molecular weight, 298.33; Rf. value
(ethyl acetate/n-hexane; 3:7), 0.78; I.R. (KBr, cm−1)
2,908.45(C-H str.), 1,662.52(conj. C = C), 1,232.43(Ar.
C-O), 665.54(Ar. C-H bend.).
Synthesis of compounds (5A-5P): general procedure
A mixture of compound, i.e., substituted chalcone (0.01 M)
(3A-3P), add 0.01 M of NaOH and urea (0.01 M) was
refluxed in ethanol for 8 to 10 h after completion of re-
action. The content was concentrated and poured into
cold water. The product so obtained was washed with
water repeatedly and recrystallized in ethanol.
Synthesis of 3,4-dihydro-4,6-diphenylpyrimidin-2







Figure 8 Percent inhibition for antioxidant activity of pyrimidine derivative.
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http://www.orgmedchemlett.com/content/4/1/33-phenyl-1-phenylprop-2-en-1-one(chalcone) (3A) (0.01 M),
add 0.01 M of NaOH and urea (0.01 M). Molecular for-
mula, C16H14N2O; molecular weight, 250.2; m. p., 111°C
to 113°C.; Rf. value (toluene/ethyl acetate/formic acid,
5:4:1), 0.64; I.R. value (KBr, cm−1), 3,319.26(N-H), 3,001.03
(Ar C-H), 1,625.88(C =O), 1,579.59(C = C), 854.53(C-H
bend.).
Synthesis of 3,4-dihydro-4-(2, 4-dimethoxyphenyl)-
6-phenylpyrimidin-2(1H)-one (5B): It was obtained by
reaction of compound 3-(2,4-dimethoxyphenyl)-1-phe-
nylprop-2-en-1-one (3B) (0.01 M), add 0.01 M of NaOH
and urea (0.01 M). Molecular formula, C18H18N2O3; mo-
lecular weight, 310.32; m. p., 121°C to 123°C.; Rf. value
(toluene/ethyl acetate/formic acid, 5:4:1), 0.68; I.R. value
(KBr, cm−1), 3,137.97(N-H), 3,008.75(Ar C-H), 1,670.24
(C = O), 1,544.88(C = C), 842.83(C-H bend.).
Synthesis of 3,4-dihydro-4-(2-methoxyphenyl)-6-phe-
nylpyrimidin-2(1H)-one (5C): It was obtained by reaction
of compound 3-(2-methoxyphenyl)-1-phenylprop-2-en-
1-one (3C) (0.01 M), add 0.01 M of NaOH and urea
(0.01 M). Molecular formula, C17H16N2O2; molecular
weight, 380.32; m. p., 132°C to 134°C.; Rf. value (toluene/
ethyl acetate/formic acid, 5:4:1), 0.76; I.R. value, 3,440.77Scheme 1 Reaction of DPPH with compound having proton.(N-H), 2,916.17(C-H str.), 1,645.17(C =O), 1,596.95(N-H
bend.), 838.98(C-H bend.).
Synthesis of 3,4-dihydro-4-(4-methoxyphenyl)-6-phenyl-
pyrimidin-2(1H)-one (5D): It was obtained by reaction
of compound 3-(4-methoxyphenyl)-1-phenylprop-2-en-
1-one (3D) (0.01 M), add 0.01 M of NaOH and urea
(0.01 M). Molecular formula, C17H16N2O2; molecular
weight, 380.32; Rf. value (toluene/ethyl acetate/formic
acid, 5:4:1), 0.78; I.R. value, 3,470.67(N-H), 2,903.63(C-H
str.), 1,684.70(C =O), 1,584.41(N-H bend.), 815.83(C-H
bend.).
Synthesis of 4-(2-chlorophenyl)-3,4-dihydro-6-phenyl-
pyrimidin-2(1H)-one (5E): It was obtained by reaction of
compound 3-(2-chlorophenyl)-1-phenylprop-2-en-1-one
(3E) (0.01 M), add 0.01 M of NaOH and urea (0.01 M).
Molecular formula, C16H13ClN2O; molecular weight,
284.74; m. p., 60°C to 62°C.; Rf. value (toluene/ethyl
acetate/formic acid, 5:4:1),0.74; I.R. value, 3,415.70(N-
H), 2,918.10(C-H str.), 1,618.17(C = O), 1,585.38(N-H
bend.), 827.41(C-H bend.). m/e, 285.1, 268.0, 249.0,
223.1, 207.0, 192.0 (100%), 183.1.
Synthesis of 4-(4-chlorophenyl)-3,4-dihydro-6-phenyl-
pyrimidin-2(1H)-one (5F): It was obtained by reaction of






Slop IC50value μg/ml r
2 AAU
1 6A 0.566 89 0.704 8.076
2 6B 0.835 94 0.322 8.13
3 6C 0.753 111 0.35 6.47
4 6D 0.764 50 0.257 9.43
5 6E 0.76 88.5 0.117 20.76
6 6F 0.912 28.5 0.312 7.69
7 6G 0.763 81 0.27 8.9
8 6H 0.891 45 0.293 8.15
9 6I 0.767 196 0.164 13.56
10 6J 0.984 0 0.249 10.05
11 6K 0.872 21.5 0.126 19.86
12 6M 0.775 68.5 0.368 5.9
13 6N 0.819 81.45 0.279 8.37
14 6P 0.761 212 0.209 11.19
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(3 F) (0.01 M), add 0.01 M of NaOH and urea (0.01 M).
Molecular formula, C16H13ClN2O; molecular weight,
284.74; m. p., 104°C to 106°C.; Rf. value (toluene/ethyl
acetate/formic acid, 5:4:1), 0.94; I.R. value, 3,442.70(N-H),
3,056.96(C-H str.), 1,635.59(C =O), 1,595.02(N-H bend.),
823.55(C-H bend.).
Synthesis of 4-(2,4-dichlorophenyl)-3,4-dihydro-6-phe-
nylpyrimidin-2(1H)-one (5G): It was obtained by reaction
of compound 3-(2,4-dichlorophenyl)-1-phenylprop-2-en-
1-one (3G) (0.01 M), add 0.01 M of NaOH and urea
(0.01 M). Molecular formula, C16H12Cl2N2O; molecular
weight, 319.19; m. p., 143°C to 145°C.; Rf. value (toluene/
ethyl acetate/formic acid, 5:4:1), 0.88; I.R. value, 3,421.48
(N-H), 2,916.17(C-H str.), 1,635.59(C =O), 1,581.52(N-H
bend.), 830.65(C-H bend.).Figure 9 AAU and IC50 value.Synthesis of 4-(2,6-dichlorophenyl)-3,4-dihydro-6-phe-
nylpyrimidin-2(1H)-one (5H): It was obtained by reaction
of compound 3-(2,6-dichlorophenyl)-1-phenylprop-2-en-
1-one (3H) (0.01 M), add 0.01 M of NaOH and urea
(0.01 M). Molecular formula, C16H12Cl2N2O; molecular
weight, 319.19; m. p., 116°C to 118°C.; Rf. value (toluene/
ethyl acetate/formic acid, −5:4:1), 0.96; I.R. value, 3,417.63
(N-H), 2,918.10(C-H str.), 1,683.74(C =O), 1,585.87(N-H
bend.), 850.86(C-H bend.).
Synthesis of 4-(4-fluorophenyl)-3,4-dihydro-6-phenyl-
pyrimidin-2(1H)-one (5I): It was obtained by reaction of
compound 3-(2-fluorophenyl)-1-phenylprop-2-en-1-one
(3I) (0.01 M), add 0.01 M of NaOH and urea (0.01 M).
Molecular formula, C16H13FN2O; molecular weight,
268.29; Rf. value (toluene/ethyl acetate/formic acid, 5:4:1),
0.78; I.R. value, 3,225.05(N-H), 2,920.03(C-H str.), 1,683.74
(C =O), 1,596.95(N-H bend.), 815.83(C-H bend.).
Synthesis of 4-(4-bromophenyl)-3,4-dihydro-6-phenyl-
pyrimidin-2(1H)-one (5K): It was obtained by reaction
of compound 3-(4-bromophenyl)-1-phenylprop-2-en-
1-one (3 K) (0.01 M), add 0.01 M of NaOH and urea
(0.01 M). Molecular formula, C16H13FN2O; molecular
weight, 268.29; Rf. value (toluene/ethyl acetate/formic
acid, −5:4:1), 0.72; I.R. value, 3,415.70(N-H), 2,921.96
(C-H str.), 1,677.95(C =O), 1,589.23(N-H bend.), 831.26
(C-H bend.).
Synthesis of 3,4-dihydro-4-(3-nitrophenyl)-6-phenyl-
pyrimidin-2(1H)-one (5M): It was obtained by reaction
of compound 3-(3-nitrophenyl)-1-phenylprop-2-en-1-
one (3 M) (0.01 M), add 0.01 M of NaOH and urea
(0.01 M). Molecular formula, C16H13N3O2; molecular
weight, 295.29; Rf. Value (toluene/ethyl acetate/formic
acid, −5:4:1), 0.75; I.R. value, 3,417.63(N-H), 2,916.17(C-
H str.), 1,677.95(C =O), 1,596.95(N-H bend.), 831.26(C-
H bend.).
Synthesis of 3,4-dihydro-4-(4-nitrophenyl)-6-phenyl-
pyrimidin-2(1H)-one (5N): It was obtained by reaction
Table 7 Growth percentage of synthesized compound against cancer cell line
Code number Mean Growth percent of cancer cells
6E 102.27 92.25 103.34 105.00 102.40 103.21 102.66 101.33 109.04 103.00
6N 89.17 76.08 85.07 95.26 92.38 89.75 93.04 87.27 88.45 92.58
6P 95.90 93.62 91.55 100.10 96.00 94.52 97.92 97.16 96.96 96.27
6C 100.69 95.66 96.75 103.51 96.14 102.20 102.64 101.08 112.87 102.25
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(3 N) (0.01 M), add 0.01 M of NaOH and urea
(0.01 M). Molecular formula, C16H13N3O2; molecular
weight, 295.29; m. p., 143°C to 145°C.; Rf. value (toluene/
ethyl acetate/formic acid, −5:4:1), 0.70; I.R. value, 3,415.70
(N-H), 2,918.10(C-H str.), 1,614.31(C =O), 1,598.88(N-H
bend.), 696.25(C-H bend.).
Synthesis of 3,4-dihydro-4-(3,4,5-trimethoxyphenyl)-
6-phenylpyrimidin-2(1H)-one (5P): It was obtained by
reaction of compound 3-(3,4,5-trimethoxyphenyl)-1-phe-
nylprop-2-en-1-one (3P) (0.01 M), add 0.01 M of NaOH
and urea (0.01 M). Molecular formula, C19H20N2O4;
molecular weight, 340.37; m. p., 66°C to 68°C; Rf. value,
(toluene/ethyl acetate/formic acid, 5:4:1), 0.82; I.R. value,
3,325.05(N-H), 2,920.03(C-H str.), 1,643.76(C = O),
1,589.23(N-H bend.), 838.98(C-H bend.).
Synthesis of compounds (6A-6P): general procedure
To a solution of 5A-5P (0.01 mol) in ethanol, β-D-
ribofuranose-1,2,3,5-tetra-o-acetate (0.01 mol) was added
in the presence of TsOH and the content were refluxed
under vacuum with stirring at 155°C to 160°C for 15 to
30 min. The vacuum was removed, and the reaction mix-
ture was protected from moisture by fitting a guard tube.
Stirring was further continued for 10 h and vacuum was
applied for 10 min. at every hour. The viscous mass thus
obtained was dissolved in sodium-containing methanol
and boiled for 10 min then left for stirring overnight at
room temperature. The reaction mixture was filtered, and
the filtrate was evaporated to dryness. The viscous residue,
thus obtained was dissolved in ether, filtered, concen-
trated, and kept in refrigerator overnight to get crystalline
product.
Synthesis of 3,4-dihydro-1-(tetrahydro-3, 4-dihydroxy-
5-(hydroxymethyl)furan-2-yl)-4, 6-diphenylpyrimidin-2
(1H)-one (6A): It was obtained from the reaction of 3,4-
dihydro-6-(phenyl)-4-phenylpyrimidin-2(1H)-one (5A)
(0.01 mol) in ethanol, β-D-ribofuranose-1,2,3,5-tetra-
o-acetate (0.01 mol) was added in the presence of
TsOH. Molecular formula, C23H26N2O7; molecular
weight, 382.41; m. p., 121°C to 123°C; Rf. value (ethyl
acetate/n-hexane. 3:7), 0.73; I.R. (KBr cm−1), 3,542.99
(O-H, str.), 3,286.48(N-H str.), 3,006.82(C-H, str.),
1,613.67 (C = C), 1,380.94 (C = O), 1,114.78 (C-O-C),
744.47(C-H, bend.). 1H-NMR (CDCl3-d, δ, ppm), 2.46
(s, 1H, NH), 3.22(s, 3H, OH), 3.81 to 3.95(d, 3H, CH2,CH), 3.99 to 4.55 (m, 4H, CH), 5.28(d, 1H, CH), 6.41 to
7.259(m, 10H, Ar-CH). m/e, 382.15(M+); elemental
analysis calculated, C, 65.96; H, 5.80; N, 7.33.
Synthesis of 3,4-dihydro-1-(tetrahydro-3,4-dihydroxy-
5-(hydroxymethyl)furan-2-yl)-6-(2,4-dimethoxyphenyl)-
4-phenylpyrimidin-2(1H)-one (6B):It was obtained from
the reaction of 3,4-dihydro-6-(2,4-dimethoxyphenyl)-4-
phenylpyrimidin-2(1H)-one (5B) (0.01 mol) in ethanol,
β-D-ribofuranose-1,2,3,5-tetra-o-acetate (0.01 mol) was
added in the presence of TsOH. Molecular formula,
C23H26N2O7; molecular weight, 442.17; m. p., 142°C to
144°C; Rf. value (ethyl acetate/n-hexane, 3:7); 0.80, IR
(KBr cm−1), 3,440.77(O-H, str.), 3,375.20(N-H, str.),
2,921.96(C-H, str.), 1,504.37 (C = C), 1,215.07 (C = O),
1,193.85 (C-O-C), 815.83(C-H, bend.). 1H-NMR (CDCl3-
d, δ, ppm), 2.59(s, 1H, NH), 3.37(s, 3H, OH), 3.54 to 3.61
(d, 3H, CH2, CH), 3.69(s, 6H, OCH3), 4.23 to 4.55 (m, 4H,
CH), 5.65 to 5.67(d, 1H, CH), 6.95 to 7.25 (m, 8H, Ar-
CH). m/e, 442.2, 417.2, 343.2, 310.0, 288.0, 213.0(100%),
165.1, 135.1. Elemental analysis calculated, C, 62.43; H,
5.92; N, 6.33.
Synthesis of 3,4-dihydro-1-(tetrahydro-3, 4-dihydroxy-
5-(hydroxymethyl)furan-2-yl)-6-(2-methoxyphenyl)-4-
phenylpyrimidin-2(1H)-one(6C): It was obtained from
the reaction of 3,4-dihydro-4-(2-methoxyphenyl)-6-phe-
nylpyrimidine-2(1H)-one(5C) (0.01 mol) in ethanol, β-D-
ribofuranose-1,2,3,5-tetra-o-acetate (0.01 mol) was added
in the presence of TsOH. Molecular formula, C22H24N2O6;
molecular weight, 412.5; m. p., 55°C to 57°C; Rf. value
(toluene/ethyl acetate/formic acid, 5:4:1), 0.92; I.R.(KBr,
cm−1), 3,487.06 (O-H, str.), 3,307.69 (N-H, str.), 2,920.03
(C-H, Ar.), 1,596.95 (C = C), 1,091.63 (C-O-C), 827.41
(C-H, bend.); 1H-NMR, 1.556(s, 1H, NH), 3.330 to
3.338(s, 3H, OH), 3.343(s, 3H, OCH3), 3.740 to 3.75(d,
2H, CH), 4.054 to 4.11(m, 4H, CH), 6.297 to 6.299(d, 2H,
CH), 6.902to 7.954(m, 9H, Ar-CH); m/e, 412.23, 362.3
(100%), 359.5, 195. Elemental analysis calculated, C, 64.07;
H, 5.87; N, 6.79.
Synthesis of 3,4-dihydro-1-(tetrahydro-3,4-dihydroxy-
5-(hydroxymethyl)furan-2-yl)-6-(4-methoxyphenyl)-4-
phenylpyrimidin-2(1H)-one (6D): It was obtained
from the reaction of 3,4-dihydro-6-(4-methoxyphenyl)-
4-phenylpyrimidin-2(1H)-one (5D) (0.01 mol) in etha-
nol, β-D-ribofuranose-1,2,3,5-tetra-o-acetate (0.01 mol)
was added in the presence of TsOH. Molecular formula,
C22H24N2O6; molecular weight, 412.44; m. p., 146°C to
Figure 10 Growth percent of cancer cells of compound 6E.
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Figure 11 Growth percent of cancer cells of compound 6N.
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Figure 12 Growth percent of cancer cells of 6P.
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Figure 13 Growth percent of cancer cells of 6C.
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       3,4-dimethoxybnzaldehyde
       2-methoxybnzaldehyde
       4-methoxybnzaldehyde
       2-chlorobenzaldehyde
       4-chlorobenzaldehyde
       2,4-dichlorobenzaldehyde
       2,6-dichlorobenzaldehyde
       2-flurobenzaldehyde 
       4-flurobenzaldehyde         
       4- bromo benzaldehyde 
        2-nitrobenzaldehyde
        3-nitrobenzaldehyde
       4-nitrobenzaldehyde
       2,4-dinitrobenzaldehyde
       3,4,5 trimethoxybenzaldehyde
Scheme 2 Reaction scheme.
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(KBr, cm−1), 3,375.20 (O-H str.), 3,286.48 (N-H, str.),
2,918.10 (C-H, Ar.), 1,598.88 (C = C), 1,134.07 (C-O-C),
815.83(C-H, bend.); 1H-NMR (CDCl3-d, δ, ppm), 2.507
(s, 1H, NH), 3.346 (s, 3H, OH), 3.607(s, 3H, OCH3),
3.654 to 3.709 (m, 5H, CH,CH2), 3.740 to 3.910(d, 3H,
CH), 4.111 to 4.13(d, 1H, CH), 6.857-7.038(m, 9H, Ar-
CH). m/e, 399.2, 365.1, 305.3, 294.0, 278.0, 249.2, 214.1




4-phenylpyrimidin-2(1H)-one (6E): It was obtained
from the reaction of 4-(2-chlorophenyl)-3, 4-dihydro-6-
phenylpyrimidine-2(1H)-one(5E) (0.01 mol) in ethanol,
β-D-ribofuranose-1,2,3,5-tetra-o-acetate (0.01 mol) was
added in the presence of TsOH. Molecular formula,
C21H21ClN2O5; molecular weight, 416; m. p., 97°C to
99°C; Rf. value (toluene/ethyl acetate/formic acid, 5:4:1),
0.89; I.R. (KBr, cm−1), 3,365.55(O-H, str.), 3,244.05(N-H,
str.), 2,850.59(C-H, str.), 1,656.74(C =O), 1,596.95 (C = C),
1,132.14 (C-O-C), 815.83(C-H, bend.), 690.47(C-Cl). 1H-NMR (CDCl3-d, δ, ppm), 0.880(d, 1H, CH), 1.254(d, 2H,
CH2), 2.591(s, 1H, NH), 3.293 to 3.479(s, 3H, OH), 3.899
to 3.982(m, 4H, CH), 6.297(d, 2H, CH), 7.257 to 8.690(m,
9H, Ar-CH). m/e, 416.13, 374.2, 360.2, 359.2 (100%), 258.9;
elemental analysis calculated, C, 60.51; H, 5.08; N, 6.72.
Synthesis of 6-(4-chlorophenyl)-3,4-dihydro-1-(tetra-
hydro-3,4-dihydroxy-5-(hydroxymethyl) furan -2–yl)-
4-phenylpyrimidin-2(1H)-one (6F): It was obtained
from the reaction of 3,4-dihydro-6-(4-chlorophenyl)-4-
phenylpyrimidin-2(1H)-one (5F) (0.01 mol) in ethanol,
β-D-ribofuranose-1,2,3,5-tetra-o-acetate (0.01 mol) was
added in the presence of TsOH. Molecular formula,
C21H21ClN2O5; molecular weight, 416.85; m. p., 65°C to
67°C; Rf. value (ethyl acetate/n-hexane, 3:7), 0.61. I.R.
(KBr cm−1), 3,475.49(O-H, str.), 3,380.98(N-H str.),
2,920.03(C-H, str.), 1,569.95 (C = C), 1,662.52 (C = 0),
1,134.07 (C-O-C), 775.33(C-Cl), 815.83(C-H, bend.). 1H-
NMR, 2.034 (s, 1H, NH), 3.034 (s, 3H, OH), 3.325 to
3.412(m, 5H, CH, CH2), 3.826 to 3.925(d, 3H, CH),
5.352(d, 1H, CH), 7.256 to 7.561(m, 8H, Ar-CH). m/e,
416.85(M+). Elemental analysis calculated, C, 60.51; H,
5.08; N, 6.72.
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(tetrahydro-3, 4-dihydroxy-5-(hydroxymethyl)furan-2-
yl)-4-phenylpyrimidin-2(1H)-one (6G): It was obtained
from the reaction of (2,4-dichlorophenyl)-3,4-dihydro-6-
phenylpyrimidin-2(1H)-one(5G) (0.01 mol) in ethanol,
β-D-ribofuranose-1,2,3,5-tetra-o-acetate (0.01 mol) was
added in the presence of TsOH. Molecular formula,
C21H20Cl2N2O5; molecular weight, 450.0; m. p., 72°C to
74°C; Rf. value (toluene/ethyl acetate/formic acid, 5:4:1),
0.77; I.R. (KBr, cm−1), 3,460.06(O-H str.), 3,175.58(N-
H, str.), 3,089.75(C-H, str.), 1,558.38 (C = C), 1,660.60
(C = O), 1,193.85 (C-O-C), 815.85(C-H, bend.), 688.54
(C-Cl). 1H-NMR (CDCl3-d, δ, ppm), 1.253(s, 1H, CH),
1.286(d, 2H, CH2), 2.034(s, 1H, NH), 3.826(s, 3H, OH),
5.352(d, 2H, CH), 7.256 to 7.561(m, 8H, Ar-CH); m/e,
450.2, 387.32, 369.42, 197.17(100%); elemental analysis
calculated, C, 55.89; H, 4.47; N, 6.21.
Synthesis of 6-(2,6-dichlorophenyl)-3,4-dihydro-1-
(tetrahydro-3,4-dihydroxy-5-(hydroxymethyl)furan-2-
yl)-4-phenylpyrimidin-2(1H)-one (6H): It was obtained
from the reaction of 3,4-dihydro-6-(2.6-dichlorophenyl)-
4-phenylpyrimidin-2(1H)-one (5H) (0.01 mol) in ethanol,
β-D-ribofuranose-1,2,3,5-tetra-o-acetate (0.01 mol) was
added in the presence of TsOH. Molecular formula,
C21H20Cl2N2O5; molecular weight, 451.3; Rf. value (ethyl
acetate/n-hexane,3:7), 0.65; I.R. (KBr cm−1), 3,419.56(O-H,
str.), 3,274.90(N-H, str.), 3,058.89(C-H, str.), 1,595.02
(C = C), 1,681.81 (C = 0), 1,178.43 (C-O-C),775.33(C-Cl),
821.62(C-H, bend.). 1H-NMR (CDCl3-d, δ, ppm), 2.800(s,
1H, NH), 3.323 to 3.402(s, 3H, OH), 3.562 to 3.662(d, 3H,
CH2, CH), 3.677 to 4.685(m, 4H, CH), 5.29 to 5.31(d, 1H,
CH), 6.910 to 7.645(m, 8H, Ar-CH). m/e, 451.3(M+);
elemental analysis calculated, C, 55.89; H, 4.47; N, 6.21.
Synthesis of 6-(2-fluorophenyl)-3,4-dihydro-1-(tetra-
hydro-3,4-dihydroxy-5-(hydroxymethyl)furan-2-yl)-4-
phenylpyrimidin-2(1H)-one (6I): It was obtained from
the reaction of 3,4-dihydro-4-(2-flurophenyl)-6-phe-
nylpyrimidine-2(1H)-one(5I) (0.01 mol) in ethanol, β-
D-ribofuranose-1,2,3,5-tetra-o-acetate (0.01 mol) was
added in the presence of TsOH. Molecular formula,
C21H21FN2O5; molecular weight, 400.14; m.p.,105°C to
107°C; Rf. value (ethyl acetate/n-hexane, 3:7), 0.52; I.R.
(KBr, cm−1), 3,363.62(O-H str.), 3,288.40 (N-H str.),
2,921.96 (C-H, Ar.), 1,600.81 (C = C), 1,134.07 (C-O-C),
815.83(C-H, bend.); 1H-NMR (CDCl3-d, δ, ppm), 2.82(s,
1H, NH), 3.33 to 3.41(s, 3H, OH), 3.55 to 3.61(d, 3H, CH2,
CH), 3.671 to 4.681(m, 4H, CH), 5.51 to 5.31(d, 1H, CH),
7.11 to 7.645(m, 9H, Ar-CH). m/e, 400.14 (M+); elemental
analysis calculated, C, 62.43; H, 5.92; N, 6.33.
Synthesis of 6-(4-fluorophenyl)-3,4-dihydro-1-(tetra-
hydro-3,4-dihydroxy-5-(hydroxymethyl) furan-2-yl)-4-
phenylpyrimidin-2(1H)-one (6J): It was obtained from
the reaction of 3,4-dihydro-4-(2-flurophenyl)-6-phenyl-
pyrimidine-2(1H)-one (5J) (0.01 mol) in ethanol, β-D-ribofuranose-1,2,3,5-tetra-o-acetate (0.01 mol) was added
in the presence of TsOH. Molecular formula, C21H21FN2O5;
molecular weight, 400.14; m. p., 94°C to 96°C; Rf. value
(ethyl acetate/n-hexane, 3:7), 0.94; I.R. (KBr, cm−1),
3,419.56 (O-H, str.), 3,380.98 (N-H, str.), 2,921.96 (C-H,
Ar.), 1,596.95 (C = C), 1,132.14 (C-O-C), 815.83(C-H,
bend.); 1H-NMR (CDCl3-d, δ, ppm), 2.51(s, 1H, NH), 3.54
(s, 3H, OH), 3.51 to 3.60(d, 3H, CH2, CH), 3.661 to 4.181
(m, 4H, CH), 5.55 to 5.61(d, 1H, CH), 7.01 to 7.345(m,
9H, Ar-CH). m/e, 400.11(M+); elemental analysis calcu-
lated, C, 62.43; H, 5.92; N, 6.33.
Synthesis of 6-(4-bromophenyl)-3,4-dihydro-1-(tet-
rahydro-3, 4-dihydroxy-5-(hydroxymethyl) furan-2-yl)-
4-phenylpyrimidin-2(1H)-one (6K): It was obtained
from the reaction of 6-(4-bromophenyl)-3,4-dihydro-4-
phenylpyrimidin-2(1H)-one (5K) (0.01 mol) in ethanol,
β-D-ribofuranose-1,2,3,5-tetra-o-acetate (0.01 mol) was
added in the presence of TsOH. Molecular formula,
C21H21BrN2O5; molecular weight, 461.31; m. p., 68°C to
70°C; Rf. value. (ethyl acetate/n-hexane, 3:7), 0.81; I.R.
(KBr, cm−1), 3,442.70(O-H, str.), 3,346.27(N-H, str.),
3,064.68 (C-H, str.), 1,604.24(C = C), 1,670.24 (C = 0),
1,174.57 (C-O-C), 640.32(C-Cl), 829.33(C-H, bend.). m/e,
413.3, 381.2, 345.0, 305.3, 249.2, 181.0, 105.0(100%).1H-
NMR (CDCl3-d, δ, ppm), 2.087(s, 1H, NH), 2.506(s, 3H,
OH), 3.357 to 3.399(m, 5H, CH, CH2), 3.467 to 3.471
(d, 2H, CH), 5.566 (d, 1H, CH), 7.543 to 7.866 (m, 9H,




phenylpyrimidin-2(1H)-one (6M): It was obtained
from the reaction of 3,4-dihydro-6-(3-nitrophenyl)-4-
phenylpyrimidin-2(1H)-one (5M) (0.01 mol) in ethanol,
β-D-ribofuranose-1,2,3,5-tetra-o-acetate (0.01 mol) was
added in the presence of TsOH. Molecular formula,
C21H21N3O7; molecular weight, 427.41; m.p., 112°C to
114°C; Rf. value (ethyl acetate/n-hexane, 3:7), 0.82; I.R.
(KBr cm−1), 3,411.84(O-H, str.), 3,319.26 (N-H, str.),
2,918.10(C-H, str.), 1,596.95(C = C), 1,658.69 (C =O),
1,174.57 (C-O-C), 1,386.72(NO2), 796.55(C-H, bend.).
1H-NMR (CDCl3-d, δ, ppm), 2.41 (s, 1H, NH), 3.23 (s,
3H, OH), 3.61 to 3.65(d, 3H, CH2, CH), 3.66 to 4.29 (m,
4H, CH), 5.51 to 5.61(d, 1H, CH), 7.13 to 7.445 (m, 9H,




phenylpyrimidin-2(1H)-one (6N): It was obtained
from the reaction of 3,4-dihydro-4-(4-nitrophenyl)-6-
phenylpyrimidin-2(1H)-one(5N) (0.01 mol) in ethanol,
β-D-ribofuranose-1,2,3,5-tetra-o-acetate (0.01 mol) was
added in the presence of TsOH. Molecular formula,
C21H21N3O7; molecular weight, 427.41; m. p., 96°C to
Dudhe et al. Organic and Medicinal Chemistry Letters 2014, 4:3 Page 17 of 18
http://www.orgmedchemlett.com/content/4/1/398°C; Rf. value (toluene/ethyl acetate/formic acid, 5:4:1),
0.89; I.R. (KBr, cm−1), 3,448.49(O-H, str.), 3,024.18(N-H,
str.), 2,918.10(C-H, str.), 1,602.74(C =O), 1,584.79 (C = C),
1,355.86 (O =N =O), 815.83 (C-H, bend.); 1H-NMR
(CDCl3-d, δ, ppm), 0.880 (d, 2H, CH2), 1.255(s, 1H, CH),
3.321 to 3.703(s, 3H, OH), 3.841 to 3.993(m, 4H, CH),
6.022(d, 2H, CH), 6.724 to 7.947(m, 9H, Ar-CH). m/e,
427.5, 367.0 (100%), 245, 167; elemental analysis calcu-
lated, C, 59.01; H, 4.95; N, 9.83.
Synthesis of 3,4-dihydro-1-(tetrahydro-3,4-dihydroxy-5-
(hydroxymethyl)furan-2-yl)-6-(3,4 5-trimethoxyphenyl)-4-
phenylpyrimidin-2(1H)-one (6P): It was obtained from
the reaction of 3,4-dihydro-4-(3, 4, 5-trimethoxyphenyl)-
6-phenylpyrimidin-2(1H)-one(5P) (0.01 mol) in ethanol,
β-D-ribofuranose-1,2,3,5-tetra-o-acetate (0.01 mol) was
added in the presence of TsOH. Molecular formula,
C24H28N2O8; molecular weight, 472; m. p., 64°C to 66°C;
Rf. value (toluene/ethyl acetate/formic acid, 5:4:1), 0.67;
I.R. (KBr, cm−1), 3,460.06(O-H, str.), 3,175.58(N-H, str.),
3,071.43(C-H, str.), 1,570.80 (C = C), 1,650.13 (C =O),
1,192.89(C-O-C), 810.51(C-H, bend.). 1H-NMR (CDCl3-d,
δ, ppm), 0.885(s, 9H, CH3), 0.878 (s, 1H, CH), 1.253(d, 2H,
CH2), 2.021(s, 1H, NH), 3.302 to 3.885 (s, 3H, OH), 6.126
(d, 2H, CH), 7.255(m, 7H, Ar-CH); m/e, 472.49, 338.3
(100%), 415.0, 167.07; elemental analysis calculated, C,
61.01; H, 5.97; N, 5.93.
Results and discussion
The scavenging effects of the synthesized compounds
6A-6P on the DPPH radical was evaluated according to
Leong and Shui et al. Various concentrations (10, 25, 50,
75, 100, and 200 μg/ml) of the test compounds in metha-
nol were added to a 0.1-mM solution of DPPH radical in
methanol. All the tests and analysis were undertaken on
three replicates and the results averaged. The antioxidant
activity of tested compounds revealed that the reaction
with DPPH is a time-dependent fashion and the higher
the concentration of the tested compounds showed the
higher the radical scavenging activity as well as percent in-
hibition and AAU. However, Compounds 6K, 6F, 6E, 6G,
6H, and 6M exhibited potent activity compared by AAU
and IC50 value. The profiles of the scavenging effect of
synthesized compounds are comparable to that of the
ascorbic acid as reference compound. The synthesized
compounds were compounds 6P, 6D, and 6M which ex-
hibited significant antifungal activity that was carried
out by cup plate method against fungal strain on strains
such as Candida inconspicua (MTCC-1074, ATCC16783),
Candida viswanathii (MTCC-1629, ATCC-22981), Can-
dida albicans (MTCC-227, ATCC-10231), Candida tropi-
calis (MTCC-230, ATCC-20336), and Candida glabrata
(MTCC-3019, ATCC-90030) against standard drug flu-
conazole. The National Institute of Health, USA, under
the drug discovery program of NCI and screened foranticancer activity at a single high dose (10−5 M) in full
NCI 60 cell lines and the compound 6E, 6N, 6P, 6C
showed anticancer activity. The introduction of bromo,
chloro, dichloro (at 2, 4 and 2, 6 positions) group
showed almost equivalent antioxidant activity as that of
the ascorbic acid. Based on the structure activity rela-
tionships, it can be concluded that the presence of halo-
gen group and methoxy group at the second, fourth,
and sixth position exhibited potent activity.Conclusions
A new series of compounds (6A-6P), i.e., pyrimidine ana-
logues, were synthesized by urea and characterized. The
synthesized compounds screened for their in vitro antioxi-
dant activity by calculating percentage scavenging, AAU
and IC50 value, antifungal activity, as well as anticancer ac-
tivity given by the derivative which has chloro, methoxy,
nitro, and chloro substitution having furanose contain pyr-
imidine derivative that showed the most potent activity.Competing interests
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